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A B S T R A C T
Objectives: : Immunological basis of neurodegenerative diseases including Alzheimer and Parkinson disease (PD)
has some important roles in their pathogenesis. There are conﬂicting studies to serum level of TNF-α in PD. Also,
according to our ﬁnding there is no report evaluating serum level of IL-27 in PD. This study correlates the serum
level of those factors with severity of PD.
Patients and methods: : In this case-control study, 83 patients with PD and 83 healthy volunteers were enrolled.
The diagnosis was fulﬁlled in accordance with clinical diagnostic criteria of the UK Parkinson's Disease Society
Brain Bank by two neurologists. The modiﬁed Hoehn and Yahr (H and Y) scale was used to evaluate the severity
of PD. Serum levels of TNF-α and IL-27 were measured by Elisa. Correlation of H and Y scale with serum levels of
these cytokines was evaluated.
Results: : The serum levels of TNF-α were increased and serum levels of IL-27 were decreased in patients with PD
compared to those in healthy subjects (P < 0.0001). There was a signiﬁcant correlation between serum levels of
TNF-α and IL-27 with H and Y scale.
Conclusion: : Our study showed that the serum levels of TNF-α and IL-27 may be important prognostic bio-
markers of PD.
1. Introduction
Parkinson Disease (PD) is the second most common progressive
neurodegenerative disease with diﬀerent clinical symptoms such as
bradykinesia, hypokinesia, tremor, cognitive dysfunction and depres-
sion. Etiology of PD is unknown, but it is clear that impairment in
dopaminergic neurons of the substantia nigra is the main factor (1–3).
Recently, some scientists have pointed to IL-1β (4), IL-6 (5), IL-10 (6) as
possible immunological factors in pathogenesis and mortality risk of the
disease.
IL-27, a cytokine with inﬂammatory and anti-inﬂammatory eﬀects,
is a member of IL-12 family. Binding to its receptor composed of gly-
coprotein 130 receptor and IL-27 receptor α chain (IL-27Rα) (7–9) on
monocytes/macrophages, mast cells, and natural killer cells (10), IL-27
inhibits the production of tumor necrosis factor-α (TNF-α) (11); and in
this way it induces its anti-inﬂammatory eﬀects. IL-27 has an essential
role in induction of Th1 diﬀerentiation and phosphorylation of STAT1
and STAT3 in CD4+ T cells (12,13). The phosphorylation of STAT3
plays a pivotal role in the inhibition of inﬂammatory cytokines (14).
Many studies have shown that IL-27 plays an important role in the
pathogenesis of some inﬂammatory diseases such as hepatitis B (15),
hepatitis C (16) and psoriasis (17). In a study, low serum level of this
cytokine was observed in patients with multiple sclerosis (18).
TNF-α, an pro-inﬂammatory cytokine produced by macrophages,
lymphoid cells and neurons (19), binds to its receptors, TNF receptor 1
(TNFR1) and TNF receptor 2 (TNFR2) (20) and activates the tran-
scription factors of nuclear factor kappa-B (NF-κB) and c-jun N-terminal
kinase (JNK). Such signaling pathways lead to inﬂammation as well as
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cell apoptosis (21–23). Many studies have revealed the pathogenic role
of TNF-α in inﬂammatory diseases such as psoriasis (24), prostate
cancer (25), rheumatoid arthritis (RA) (26) and multiple sclerosis (MS)
(27). Several studies have recently been published dissecting the role of
TNF-α in pathogenesis of PD. So that, increased (28,29) and no changes
(30) of TNF-α serum level has been reported in PD. However, there has
been a direct relationship between serum level of such cytokine with
some clinical symptoms of PD including anxiety, depression, fatigue
(30) and non-motor symptoms (31).
Serum level of TNF-α has shown some contradictions in previous
studies on patients with PD. In addition, according to our knowledge,
there are no studies evaluating the serum levels of IL-27 in such pa-
tients. The other matter is that changes in serum levels of TNF-α and IL-
27 may have close relationship with severity of the disease. Considering
such concepts, we aimed to correlate serum levels of TNF-α and IL-27 to
PD severity. Such evaluation may suggest their prognostic value and
also may render some therapeutic clues.
2. Material and methods
2.1. Study subjects
In our case-control study, 83 patients with PD and 83 healthy vo-
lunteers were enrolled. The diagnosis of PD was fulﬁlled in accordance
with clinical diagnostic criteria of the UK Parkinson Disease Society
Brain Bank by two neurologists (32). All patients were treated with L-
dopa. The exclusion criteria were any other chronic inﬂammatory/au-
toimmune diseases. The severity of the disease was assessed by mod-
iﬁed Hoehn and Yahr staging (H and Y). Our study was approved by the
local Ethics Committee and informed consent was obtained from all
participants.
2.2. Blood sample
Peripheral venous blood samples were collected from the patients
Table 1
Basic and clinical characteristic of patients with PD and health subjects.
PD patients Healthy subjects P. value
Number of subjects 83 83 –
Male/female 52/31 38/45 0.029
Age (years)(Mean ± S.D) 65.73 ± 11.20 64.20 ± 12.61 0.5
Disease duration (years) 4.94 ± 3.92
Treatment duration (years) 3.79 ± 3.55
H and Y scale (Mean ± S.D) 2/24 ± 0/73
TNF-α serum levels(pg/ml) 6 ± 3.32 3.22 ± 2.47 0.0001
IL-27 serum levels(pg/ml) 2.79 ± 1.55 4 ± 2.54 0.0001
Fig. 1. Mean and 95% conﬁdence interval of serum levels of IL-27 (pg/ml)
and TNF-α (pg/ml) in patients with PD and healthy subjects. * represents
P < 0.0001; vs. values in the healthy subjects.
Table 2
Values of TNF-α and IL-27 according to diﬀerent varieties in patients with PD.
Variables TNF-α (pg/ml) P. value IL-27 (pg/ml) P. value
H and Y Mild 4.65 ± 1.68 0.0001 2.1 ± 0.71 0.0001
Moderate 7.65 ± 4.07 3.58 ± 1.79
Severe 11.43 6.87
Sex Male 5.54 ± 3.08 0.1 2.6 ± 1.38 0.24
Female 6.77 ± 3.6 3.15 ± 1.8
Age <60 6.51 ± 4.29 0.36 2.7 ± 1.62 0.77




0-6 5.63 ± 2.94 0.05 2.41 ± 1.23 0.032
7-12 6.25 ± 3.18 3.43 ± 2.02




0-6 5.63 ± 2.98 0.13 2.47 ± 1.24 0.56
7-12 7.2 ± 3.84 3.57 ± 2.07
13-18 8.42 ± 8.31 3.94 ± 1.79
Table 3








Age −0.094 0.399 −0.004 0.976
Sex 0.18 0. 1 0.169 0.241
H and Y scale 0.674 0.0001 0.782 0.0001
Disease duration 0.321 0.003 0.442 0.001
Treatment
duration
0.318 0.003 0.427 0.002
Table 4
Linear multiple regression analysis evaluating the eﬀect of diﬀerent variables on the
serum levels of TNF-α and IL-27 in patients with PD.
Variables Coeﬃcients T Sig. P Adjusted R
Square
B Std. error
TNF-α H and Y scale 3.262 0.365 8.941 0.0001 0.504
Sex −0.834 0.534 −1.563 0.122
Age −0.071 0.024 −3.008 0.004
IL-27 H and Y scale 1.595 0.19 8.409 0.0001 0.593
Sex 0.036 0.304 0.117 0.908
Age −013 0.15 −0.847 0.401
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and healthy controls. Blood samples were allowed to be clotted and
then centrifuged (Hettich D-78532, Tuttlingen, Germany) at 3500 rpm
for 10min and the serum was separated. Then, stored frozen at−80 °C.
Serum levels of TNF-α and IL-27 were measured by commercially
available enzyme-linked immune sorbent assay (ELISA) kit (My
Biosource, USA) (33).
2.3. Statistical analysis
The serum level of TNF-α and IL-27 were analyzed by independent t
and chi-square tests. Correlations between variables were calculated by
Pearson’s correlation coeﬃcient, and simultaneous eﬀects of various
factors on these cytokines were analyzed by multiple linear regressions
with backward method. Adjusted R Squared was determined as a cri-
terion of goodness-of-ﬁt test, and P < 0.2 was considered for exclusion
from the model. P < 0.05 was considered statistically signiﬁcant.
3. Results
The clinical characteristics and laboratory ﬁndings of the patients
and controls are summarized in Table 1. The mean serum levels of TNF-
α in patients with PD were signiﬁcantly higher than those in healthy
subjects (P < 0.0001). However, serum levels of IL-27 in patients with
PD were signiﬁcantly lower than those in healthy subjects
(P < 0.0001) (Fig. 1).
Diﬀerent values of TNF-α and IL-27 serum levels according to dif-
ferent variables are shown in Table 2. Serum levels of TNF-α and IL-27
were signiﬁcantly higher in severe forms of PD than those in mild and
moderate forms (P < 0.0001) (Table 2). They were also signiﬁcantly
higher in patients suﬀering longer times from the disease than those
suﬀering shorter times (P≤ 0.05) (Table 2).
The correlation between the serum levels of TNF-α and IL-27 with
diﬀerent parameters are shown in Table 3. There were signiﬁcant
correlations between the serum levels of both TNF-α and IL-27 with
disease duration, treatment duration and severity of PD according to H
and Y scale (Table 3).
Linear multiple regression analysis showed that increase in TNF-α
serum levels is positively associated with severity of PD and age
(P≤ 0.004). In addition, the serum levels of IL-27 were found to be
associated with severity of PD (P < 0.0001) (Table 4).
4. Discussion
Considering the severity of the PD, we demonstrated a close cor-
relation between serum levels of TNF-α and PD severity in line
(30,31,34) and against (29) with other studies. Comoglu et al. found no
correlation between levels of TNF-α and severity of motor and non-
motor symptoms in PD patients according to mini-mental scale ex-
amination (MMSE), H and Y, and uniﬁed Parkinson's disease rating
scale (UPDRS) criteria (35).
Conﬁrming (28,31,34,35) and in contrast (29,30) to others, we re-
ported an increased serum levels of TNF-α in PD. TNF-α has been
shown to be related to the pathogenesis of other neurodegenerative
diseases such as Alzheimer disease (36) and Multiple sclerosis (27).
Actually, the neuronal death occurred in dopaminergic neurons
through apoptosis (37) is induced by TNF-α in PD (22,38). Enhancing
the inﬂammation, TNF-α may also play some roles in induction of IL-8
through histone acetylation and activation of NF-κB signaling pathway
(23).
We believe that our study is the ﬁrst report on serum level of IL-27
in patients with PD. In recent studies, conﬂicting results from the point
of serum levels of IL-27 in diﬀerent autoimmune diseases have been
reported. Increased serum level of IL-27 has been reported in patients
with systemic sclerosis (39) and rheumatoid arthritis (40) and its re-
duced serum level has been reported in systemic lupus erythematous
(SLE) (41,42). In the latter study, there was no correlation between
serum levels of IL-27 with disease severity (42). Babaloo et al. reported
lower serum levels of IL-27 in the neurodegenerative disease of MS
(43). Mechanistically, IL-27 regulates secretion of IL-10 as an anti-in-
ﬂammatory cytokine (44), and in this way it may have an important
role in control of inﬂammation in PD. Moreover, IL-27 induces in-
hibitory eﬀects on T helper 17 (Th17) cells. Such eﬀect may introduce
IL-27 as a therapeutic target for autoimmune/inﬂammatory states
(45,46) such as PD. A previous study showed that lower expression of
IL-27 associated with an increased Th17 response leads to an auto-
immune response in Vogt-Koyanagi-Harada disease (47). Therefore,
reduction of serum levels of IL-27 in our study may contribute to in-
creased inﬂammatory action of Th17 and autoimmune responses which
may be related to pathogenesis of PD. Our ﬁndings showed a close
relationship between serum levels of IL-27 with severity of PD. Al-
though serum level of IL-27 in patients with PD is totally lower than
that in healthy subjects, it is likely that more production of IL-27 in
more severe forms of PD is a compensatory mechanism that tries to
resolve the malicious inﬂammatory condition of the disease during the
time.
Our study had some limitations. We did not assess gene expression
levels of TNF-α and IL-27 in PD. In addition, we did not evaluate the
molecular mechanisms of the function of such cytokines in PD.
Overall, our ﬁnding showed that serum levels of TNF-α increase and
IL-27 reduce in patients with PD. Also, there was close correlation be-
tween disease severities of PD with changes in serum levels of TNF-α
and IL-27. Such cytokines may be important prognostic biomarkers of
PD.
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